Allos Therapeutics Reports Second Quarter Results

Allos Therapeutics has reported a net loss of $16.8 million, or $0.19 per share for second quarter of 2009, compared to a net loss of $11.8 million, or $0.16 per share, for the second quarter of 2008.

For the six months ended June 30, 2009, the company reported a net loss of $32 million, or $0.38 per share, as compared to a net loss of $23.8 million, or $0.34 per share, for the same period last year.

Paul Berns, president and chief executive officer of Allos Therapeutics, said: “During the quarter, we made significant progress toward our goal of obtaining approval for pralatrexate for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma and advancing our solid tumor program.

Most notably, the FDA accepted our NDA for pralatrexate for priority review and established a Prescription Drug User Fee Act date of September 24, 2009 for a decision regarding approval of the NDA. In addition, we recently achieved an important milestone with the completion of patient enrollment in our randomized Phase 2b clinical trial of pralatrexate for the treatment of patients with advanced non-small cell lung cancer,” he added.